Retrospective study of efficacy of intravesical bcg alone in treatment of superficial bladder cancer

Jack H. Mydlo, Sol M. Usher, Fernando J. Camacho, Selwyn Freed

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This is a review of 100 patients at our institution who were treated for superficial bladder cancer. In those patients with carcinoma in situ of the bladder who were treated with conventional therapy (resection and/or fulguration) and intravesical bacillus Calmette-Guerin (BCG) without intradermal BCG, and those patients who were treated with conventional therapy alone, we found a response rate of 60 per cent versus 40 per cent at the end of three months. In comparing those patients with superficial papillary cancer, we found a response of 39 per cent after conventional therapy and 63 per cent after conventional therapy and intravesical BCG. This suggests that intravesical BCG without intradermal BCG can be an important adjunct to the conventional therapy of bladder tumors.

Original languageEnglish (US)
Pages (from-to)173-175
Number of pages3
JournalUrology
Volume28
Issue number3
DOIs
StatePublished - Jan 1 1986

Fingerprint

Mycobacterium bovis
Urinary Bladder Neoplasms
Retrospective Studies
Therapeutics
Carcinoma in Situ
Urinary Bladder
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Retrospective study of efficacy of intravesical bcg alone in treatment of superficial bladder cancer. / Mydlo, Jack H.; Usher, Sol M.; Camacho, Fernando J.; Freed, Selwyn.

In: Urology, Vol. 28, No. 3, 01.01.1986, p. 173-175.

Research output: Contribution to journalArticle

Mydlo, Jack H. ; Usher, Sol M. ; Camacho, Fernando J. ; Freed, Selwyn. / Retrospective study of efficacy of intravesical bcg alone in treatment of superficial bladder cancer. In: Urology. 1986 ; Vol. 28, No. 3. pp. 173-175.
@article{2f523151bc984aeca132bf27946a96e3,
title = "Retrospective study of efficacy of intravesical bcg alone in treatment of superficial bladder cancer",
abstract = "This is a review of 100 patients at our institution who were treated for superficial bladder cancer. In those patients with carcinoma in situ of the bladder who were treated with conventional therapy (resection and/or fulguration) and intravesical bacillus Calmette-Guerin (BCG) without intradermal BCG, and those patients who were treated with conventional therapy alone, we found a response rate of 60 per cent versus 40 per cent at the end of three months. In comparing those patients with superficial papillary cancer, we found a response of 39 per cent after conventional therapy and 63 per cent after conventional therapy and intravesical BCG. This suggests that intravesical BCG without intradermal BCG can be an important adjunct to the conventional therapy of bladder tumors.",
author = "Mydlo, {Jack H.} and Usher, {Sol M.} and Camacho, {Fernando J.} and Selwyn Freed",
year = "1986",
month = "1",
day = "1",
doi = "10.1016/0090-4295(86)90036-1",
language = "English (US)",
volume = "28",
pages = "173--175",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Retrospective study of efficacy of intravesical bcg alone in treatment of superficial bladder cancer

AU - Mydlo, Jack H.

AU - Usher, Sol M.

AU - Camacho, Fernando J.

AU - Freed, Selwyn

PY - 1986/1/1

Y1 - 1986/1/1

N2 - This is a review of 100 patients at our institution who were treated for superficial bladder cancer. In those patients with carcinoma in situ of the bladder who were treated with conventional therapy (resection and/or fulguration) and intravesical bacillus Calmette-Guerin (BCG) without intradermal BCG, and those patients who were treated with conventional therapy alone, we found a response rate of 60 per cent versus 40 per cent at the end of three months. In comparing those patients with superficial papillary cancer, we found a response of 39 per cent after conventional therapy and 63 per cent after conventional therapy and intravesical BCG. This suggests that intravesical BCG without intradermal BCG can be an important adjunct to the conventional therapy of bladder tumors.

AB - This is a review of 100 patients at our institution who were treated for superficial bladder cancer. In those patients with carcinoma in situ of the bladder who were treated with conventional therapy (resection and/or fulguration) and intravesical bacillus Calmette-Guerin (BCG) without intradermal BCG, and those patients who were treated with conventional therapy alone, we found a response rate of 60 per cent versus 40 per cent at the end of three months. In comparing those patients with superficial papillary cancer, we found a response of 39 per cent after conventional therapy and 63 per cent after conventional therapy and intravesical BCG. This suggests that intravesical BCG without intradermal BCG can be an important adjunct to the conventional therapy of bladder tumors.

UR - http://www.scopus.com/inward/record.url?scp=0022990614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022990614&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(86)90036-1

DO - 10.1016/0090-4295(86)90036-1

M3 - Article

VL - 28

SP - 173

EP - 175

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -